Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $41.0 million.

  • CytomX Therapeutics' Total Current Liabilities fell 6558.78% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year decrease of 6558.78%. This contributed to the annual value of $85.8 million for FY2024, which is 4498.73% down from last year.
  • CytomX Therapeutics' Total Current Liabilities amounted to $41.0 million in Q3 2025, which was down 6558.78% from $39.2 million recorded in Q2 2025.
  • CytomX Therapeutics' Total Current Liabilities' 5-year high stood at $155.9 million during Q4 2023, with a 5-year trough of $39.2 million in Q2 2025.
  • Moreover, its 5-year median value for Total Current Liabilities was $94.6 million (2022), whereas its average is $102.5 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Total Current Liabilities surged by 9597.79% in 2022, and later crashed by 7254.41% in 2025.
  • CytomX Therapeutics' Total Current Liabilities (Quarter) stood at $77.9 million in 2021, then skyrocketed by 95.98% to $152.6 million in 2022, then increased by 2.17% to $155.9 million in 2023, then tumbled by 44.99% to $85.8 million in 2024, then tumbled by 52.17% to $41.0 million in 2025.
  • Its last three reported values are $41.0 million in Q3 2025, $39.2 million for Q2 2025, and $50.2 million during Q1 2025.